Breast Cancer Now media statements
We respond to NICE decision to approve Enhertu for people with HER2-low metastatic breast cancer
Claire Rowney chief executive of Breast Cancer Now says :
We respond to the latest report from the National Audit of Metastatic Breast Cancer
Melanie Sturtevant associate director of policy, evidence and influencing at Breast Cancer Now says: “This latest report from the National A...
We respond to SMC decision to recommend elacestrant, and capivasertib with fulvestrant, for NHS use in Scotland
Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:
We respond to the publication of new cancer incidence figures for Scotland
Frances Logan, policy and public affairs lead, Scotland at Breast Cancer Now said: “Today’s figures should be a stark reminder for the Scott...
We respond to Lisa Faulkner's news that she has been diagnosed with breast cancer
Sally Kum, associate director of nursing and health information at Breast Cancer Now, said:
We respond to NICE provisionally rejecting inavolisib with palbociclib and fulvestrant for certain people with metastatic breast cancer
Claire Rowney chief executive of Breast Cancer Now says:
We respond to the NICE cost-effectiveness threshold changing
“We welcome the new cost-effectiveness threshold coming into force, a change we’ve called for as part of our tireless campaigning to ensure ...
We respond to Beverley Callard's news that she has been diagnosed with breast cancer
Sally Kum, associate director of nursing and health information, at Breast Cancer Now, said:
We respond to commitment to tackle screening inequalities in Cancer Plan
As the UK Government announces the Neighbourhood Early Diagnosis Fund for Cancer Alliances, Claire Rowney, chief executive of Breast Cancer ...
We respond to announcement of UK database to support people the most at risk of cancer
Claire Rowney, chief executive of Breast Cancer Now, said: